Clinical trials: Living-Kidney Donors
Renal Failure
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
- Trial name
- NCT01976390
- Testing
- Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University
Utilization, Health Care, Obesity
Healthcare Utilization in Obese Caregiver Living Donors
The goal of this study is to estimate risk of post-donation healthcare use attributable to informal caregiving among obese living donors.
- Trial name
- NCT04341896
- Testing
- Caregivers, Non-caregivers
- Where
- United States
- Volunteers
- 784 people
- Sponsor
- University of Alabama at Birmingham
Kidney Transplant
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
A strongly positive crossmatch has long been considered an absolute contraindication to kidney transplantation and most patients with anti-human leukocyte antigen (HLA) antibody never were able to receive a kidney transplant.
- Trial name
- NCT00670774
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mark Stegall
Renal Transplant Recipients
Research Study of ATG and Rituximab in Renal Transplantation
The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
- Trial name
- RESTARRT (NCT01318915)
- Testing
- ATG, Rituximab, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Transplant; Failure, Kidney, EBV
Belatacept 3 Month Post Transplant Conversion Study
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to belatacept (Nulojix®) between three (3) and six (6) months after kidney transplantation.
- Trial name
- NCT02213068
- Testing
- belatacept, Tacrolimus, MPA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Lorenzo Gallon
Liver Transplantation
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
- Trial name
- NCT01888432
- Testing
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Where
- 42 sites in United States, Canada and 11 more
- Volunteers
- 285 people
- Sponsor
- Novartis Pharmaceuticals
End-stage Renal Disease, Chronic Kidney Diseases
Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication
The study is a- 2-arm randomized controlled trial among patients presenting for kidney transplant evaluation at a single transplant center to compare the effects of a patient-based self-learning and outreach intervention about…
- Trial name
- KidneyTIME (NCT05154773)
- Testing
- Kidney donation and transplant information made easy
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- State University of New York at Buffalo
Kidney Transplantation
Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation
This randomized trial will enroll adult recipients of HLA-identical living kidney transplants who are at least 1 year post-transplant.
- Trial name
- NCT01053221
- Testing
- Mycophenolic Acid, Standard of Care: CNI and MPA
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Wisconsin, Madison
Living-Donor Kidney Transplant, Kidney Transplant Recipients
Treg Modulation With CD28 and IL-6 Receptor Antagonists
The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.
- Trial name
- NCT04066114
- Testing
- lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Disorder Related to Renal Transplantation
Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
The purpose of this study is to determine whether Campath-1H induction and the associated lymphocyte depletion will permit long-term rejection-free renal allograft survival in the absence of ongoing corticosteroid administration.
- Trial name
- NCT00167661
- Testing
- Campath-1H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Wisconsin, Madison
Renal Disease
Remote Ischemic Preconditioning Living Donor Renal Transplant Protocol
In this study, patients undergoing live donor kidney transplantation will be allocated to the control group or remote ischemic preconditioning group (RIPC).
- Trial name
- NCT03084666
- Testing
- Zimmer ATS tourniquet system
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Kidney Transplantation
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
The purpose of this research study is to determine whether kidney transplant recipients who receive belimumab (Benlysta®), combined with the standard of care medications for kidney transplant recipients, is safe and effective in…
- Trial name
- CAMPBEL (NCT03591380)
- Testing
- Belimumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Kidney Diseases, Kidney Failure, Chronic
Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation
The purpose of this study was to investigate whether lower limb ischaemic preconditioning can improve renal function in patients undergoing living donor kidney transplantation
- Conditions
- Kidney Diseases, Kidney Failure, Chronic, Kidney Failure, Renal Insufficiency
- Trial name
- NCT01289548
- Testing
- remote ischaemic preconditioning
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Huazhong University of Science and Technology
Kidney Transplant Failure and Rejection
A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
This is an open label, single-center, randomized phase IV pilot study of steroid and calcineurin inhibitor avoidance in renal transplant recipients.
- Trial name
- Cell220 (NCT00166712)
- Testing
- Tacrolimus (TAC), Sirolimus, Alemtuzumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Quadratus Lumborum Block, Surgical Wound Infiltration
Surgeon Infiltration QL Block Comparison
The purpose of this study is to learn if using a Quadratus Lumborum (QL) plane injection technique (also called a "nerve block") that numbs the nerves going to the abdominal area improve pain control after surgery compared to…
- Trial name
- NCT03496610
- Testing
- Liposomal Bupivicaine, QL Block
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University
Chronic Kidney Diseases, Apolipoprotein L1
APOL1 Genetic Testing Program for Living Donors
Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves.
- Conditions
- Chronic Kidney Diseases, Apolipoprotein L1, Kidney Transplantation
- Trial name
- NCT04910867
- Testing
- Components of Genetic Counseling, APOL1 genetic testing, EHR integration
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- Northwestern University
Kidney Transplant
Reducing Disparities in Living Donor Transplant Among African Americans
For most of the patients in the United States with end stage renal disease (ESRD), kidney transplantation represents the optimal treatment, and living donor kidney transplantation (LDKT) is preferable.
- Trial name
- NCT03819686
- Testing
- Living ACTS website, Standard transplant education procedures
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Emory University
Pain
Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System
The purpose of this study is to determine if the Airseal System will reduce post-operative pain and reduce the need for narcotics in laparoscopic living kidney donor surgeries.
- Trial name
- NCT02262039
- Testing
- Valveless recirculating insufflation (VTI), Conventional pressure
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Kidney Transplant
Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
The purpose of this study is to try to determine if the drug eculizumab can help prevent antibody-mediated rejection in patients undergoing a kidney transplant from a living donor with a different blood type than their own.
- Trial name
- ABOi (NCT01095887)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Antibody Mediated Rejection
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization…
- Trial name
- NCT01399593
- Testing
- Eculizumab
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Alexion Pharmaceuticals, Inc.